Identification of the di‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti‐tumour agents
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In an attempt to develop chelators as potent anti‐tumour agents, we synthesized two series of novel ligands based on the very active 2‐pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) group. Since lipophilicity and membrane permeability play a critical role in Fe chelation efficacy, the aldehyde moiety of the PCIH series, namely 2‐pyridylcarboxaldehyde, was replaced with the more lipophilic 2‐quinolinecarboxaldehyde or di‐2‐pyridylketone moieties. These compounds were then systematically condensed with the same group of acid hydrazides to yield ligands based on 2‐quinolinecarboxaldehyde isonicotinoyl hydrazone (QCIH) and di‐2‐pyridylketone isonicotinoyl hydrazone (PKIH). To examine chelator efficacy, we assessed their effects on proliferation, Fe uptake, Fe efflux, the expression of cell cycle control molecules, iron‐regulatory protein‐RNA‐binding activity, and 3 H‐thymidine, 3 H‐uridine and 3 H‐leucine incorporation. Despite the high lipophilicity of the QCIH ligands and the fact that they have the same Fe‐binding site as the PCIH series, surprisingly none of these compounds were effective. In contrast, the PKIH analogues showed marked anti‐proliferative activity and Fe chelation efficacy. Indeed, the ability of these ligands to inhibit proliferation and DNA synthesis was similar or exceeded that found for the highly cytotoxic chelator, 311. In contrast to the PCIH and QCIH analogues, most of the PKIH group markedly increased the mRNA levels of molecules vital for cell cycle arrest. In conclusion, our studies identify structural features useful in the design of chelators with high anti‐proliferative activity. We have identified a novel class of ligands that are potent Fe chelators and inhibitors of DNA synthesis, and which deserve further investigation. British Journal of Pharmacology (2003) 138, 819–830. doi:10.1038/sj.bjp.0705089
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 2×
“…Fe chelation e cacy (Figures 3 ± 5) and high anti-proliferative activity (Table 2) of the PKIH ligands, it was important to determine their e ect on the expression of the genes WAF1 and GADD45 that encode cell cycle inhibitors essential for G1-S arrest (El-Deiry et al., 1993; Kastan et al., 1992).”
BackgroundHentze, M. W., & Kühn, L. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8175 · Cited by 1,292
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267
Cited by
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationWhitnall, M., Howard, J., Ponka, P., & Richardson, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604979103 · Cited by 509
Self-citationYu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Self-citationRichardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., & Bernhardt, P. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606342 · Cited by 383
Self-citationYuan, J., Lovejoy, D. B., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-03-0868 · Cited by 381
Self-citation
Metadata
- Authors
- Becker, E. M., Lovejoy, D. B., Greer, J. M., Watts, R., & Richardson, D. R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 138
- Issue
- 5
- Pages
- 819-830
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2000302463
- Cited by
- 103
- References
- 3
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of the di‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti‐tumour agents. https://app.cochat.ai/papers/10.1038/sj.bjp.0705089
- The paper
- Becker, E. M., Lovejoy, D. B., Greer, J. M., Watts, R., & Richardson, D. R. (2003). Identification of the di‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti‐tumour agents. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0705089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.